Provided by Tiger Trade Technology Pte. Ltd.

RAPT Therapeutics, Inc.

33.18
-0.8500-2.50%
Post-market: 33.08-0.1000-0.30%16:10 EST
Volume:351.49K
Turnover:11.67M
Market Cap:919.45M
PE:-5.03
High:35.17
Open:34.14
Low:31.70
Close:34.03
52wk High:42.39
52wk Low:5.67
Shares:27.71M
Float Shares:13.26M
Volume Ratio:0.90
T/O Rate:2.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.5969
EPS(LYR):-25.4880
ROE:-85.37%
ROA:-51.35%
PB:6.05
PE(LYR):-1.30

Loading ...

RAPT Therapeutics Inc - Rpt904 Shows Comparable Efficacy to Omalizumab

THOMSON REUTERS
·
Oct 20

RAPT Therapeutics Inc - Jeyou to Advance Rpt904 to Phase 3 in China

THOMSON REUTERS
·
Oct 20

RAPT Therapeutics Announces Topline Results from Phase 2 Trial of RPT904 in Chronic Spontaneous Urticaria

Reuters
·
Oct 19

RAPT Therapeutics to Report Topline Data From Phase 2 Clinical Trial of Rpt904 in Chronic Spontaneous Urticaria (Csu)

THOMSON REUTERS
·
Oct 19

RAPT Therapeutics: Anticipated Catalysts and Growth Potential Drive Buy Rating

TIPRANKS
·
Oct 11

RAPT Therapeutics Receives FDA Clearance to Begin Phase 2b Clinical Trial of RPT904 for Food Allergy Treatment

Reuters
·
Sep 29

RAPT Therapeutics Announces FDA Clearance of Ind Application to Proceed to Phase 2B Trial of Rpt904 in Food Allergy

THOMSON REUTERS
·
Sep 29

RAPT Therapeutics Shares Rise After Leerink Partners Upgrade

MT Newswires Live
·
Sep 27

BUZZ-Rapt Therapeutics climbs after Leerink Partners upgrades to 'outperform'

Reuters
·
Sep 26

RAPT Therapeutics Shares Rise 3.1% Premarket After Leerink Partner Raises to Outperform From Market Perform

THOMSON REUTERS
·
Sep 26

Leerink Partners Upgrades RAPT Therapeutics to Outperform From Market Perform, Adjusts PT to $37 From $16

MT Newswires Live
·
Sep 26

RAPT Therapeutics Inc. to Participate in Multiple Investor Conferences in September 2025

Reuters
·
Aug 27

Rapt Therapeutics Is Maintained at Neutral by UBS

Dow Jones
·
Aug 12

UBS Adjusts Price Target on RAPT Therapeutics to $9 From $8, Maintains Neutral Rating

MT Newswires Live
·
Aug 12

RAPT Therapeutics Q2 EPS $(0.65) Misses $(0.63) Estimate

Benzinga
·
Aug 07

RAPT Therapeutics Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
Aug 04

RAPT Therapeutics Shares Rise After JPMorgan Upgrade

MT Newswires Live
·
Jul 31

JPMorgan Upgrades RAPT Therapeutics to Neutral From Underweight, Price Target is $14

MT Newswires Live
·
Jul 30

U.S. RESEARCH ROUNDUP-Penumbra, UnitedHealth, Visa

Reuters
·
Jul 30

Rapt Therapeutics Inc. Files Initial Beneficial Ownership Statement for Director Ashley L. Dombkowski

Reuters
·
Jul 01